Quick Answer
4D Molecular Therapeutics, Inc. reported Total Revenue of $85.21 million for the year ending 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +230,194.6% in Total Revenue from 2024 to 2025.
- This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2019 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $3.41 million | Q1 2020: $3.54 million | Q2 2020: $3.51 million | Q2 2020: $3.63 million | Q3 2020: $7.42 million | Q3 2020: $7.42 million | Q1 2021: $2.00 million | Q1 2021: $2.00 million | Q2 2021: $14.58 million | Q2 2021: $14.58 million | Q3 2021: $1.37 million | Q3 2021: $1.37 million | Q1 2022: $1.22 million | Q1 2022: $1.22 million | Q2 2022: $162.0 thousand | Q2 2022: $162.0 thousand | Q3 2022: $500.0 thousand | Q3 2022: $500.0 thousand | Q1 2023: $298.0 thousand | Q2 2023: $239.0 thousand | Q3 2023: $20.20 million | Q1 2024: $28.0 thousand | Q2 2024: $5.0 thousand | Q3 2024: $3.0 thousand | Q1 2025: $14.0 thousand | Q2 2025: $15.0 thousand | Q3 2025: $90.0 thousand.
- Over the full 10 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Total Revenue has grown by 1,124.3%.
- Historical annual values: Fiscal year 2025: $85.21 million | Fiscal year 2024: $37.0 thousand | Fiscal year 2023: $20.72 million | Fiscal year 2022: $3.13 million | Fiscal year 2021: $18.04 million | Fiscal year 2021: $18.04 million | Fiscal year 2020: $13.61 million | Fiscal year 2020: $13.36 million | Fiscal year 2019: $6.99 million | Fiscal year 2019: $6.96 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: